首页|卵巢癌铂类化疗耐药的分子机制研究进展

卵巢癌铂类化疗耐药的分子机制研究进展

Advances in molecular mechanisms of resistance to platinum chemotherapy in ovarian cancer

扫码查看
铂类药物是卵巢癌最有效的化疗药物之一,虽然铂类化疗的初始反应高达80%,但耐药性很常见.在大多数晚期患者中,最终复发和死亡是由获得性耐药所引起.卵巢癌化疗耐药性是影响其治疗效果的重大障碍,然而化疗耐药其病因不清、机制复杂,是临床及科研中急需解决的难点和热点.因此,卵巢癌耐药机制的研究将为卵巢癌化疗的探索及研发提供依据.现关于卵巢癌铂类耐药的分子机制进行综述.
Platinum drugs are one of the most effective chemotherapy drugs for ovarian cancer,and although the initial response to platinum chemotherapy is as high as 80%,resistance is common.In most advanced patients,eventual relapse and death are caused by acquired resistance.Chemotherapy resistance of ovarian cancer is a major obstacle affecting its therapeutic effect.However,the cause of chemotherapy resistance is unclear and the mechanism is complex,which is a difficult and hot point in clinical and scientific research.Therefore,the study of drug resistance mechanism of ovarian cancer will provide a basis for the exploration and development of chem-otherapy for ovarian cancer.This article reviews the molecular mechanism of platinum resistance in ovarian cancer.

ovarian cancerplatinum chemotherapy resistancemolecular mechanism

刘影、梁义娟、解丹、闫丽伟、刘璐、王伟明

展开 >

河北大学附属医院妇科, 河北 保定 071000

河北大学临床医学院, 河北 保定 071000

卵巢癌 铂类化疗耐药性 分子机制

河北省政府项目河北大学医学学科培育项目

ZF20242182020B06

2024

医学研究与教育
河北大学

医学研究与教育

影响因子:0.675
ISSN:1674-490X
年,卷(期):2024.41(1)
  • 59